You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 252 Immune-related adverse events associated with immune checkpoint inhibitor therapy are associated with enhanced survival and disease-specific incidence

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Checkpoint blockade therapy
252 Immune-related adverse events associated with immune checkpoint inhibitor therapy are associated with enhanced survival and disease-specific incidence

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 202066012
Dec 202036014
Jan 20213505
Feb 20215808
Mar 20214107
Apr 20213203
May 20215012
Jun 20210010
Jul 2021007
Aug 2021008
Sep 2021002
Oct 202148022
Nov 202132020
Dec 2021802
Jan 20222402
Feb 20221006
Mar 20221005
Apr 20223403
May 20222805
Jun 20221204
Jul 20221007
Aug 20221005
Sep 20221202
Oct 20221002
Nov 20221201
Dec 20221603
Jan 20233407
Feb 20231200
Mar 20231203
Apr 2023200
May 20231202
Jun 2023602
Jul 20231004
Aug 2023400
Sep 2023600
Oct 20231003
Nov 20231602
Dec 20231401
Jan 20241400
Feb 20241801
Mar 20241603
Apr 20241601
May 20241802
Jun 20242405
Jul 2024600
Aug 20241003
Sep 20241002
Oct 2024802
Nov 20241502
Dec 2024604
Jan 20252008
Feb 2025004
Mar 2025106
Apr 2025004
May 2025003
Jun 2025103
Total8700254